Tildrakizumab for moderate-to-severe psoriasis in Canada
Part of Skin clinical trials.
This study looks at how well tildrakizumab works for people with moderate-to-severe plaque psoriasis who are starting this treatment through a support program in Canada. Researchers want to see how it affects your symptoms and daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate-to-severe plaque psoriasis covering at least 3% of your body, and your skin type is Fitzpatrick type III or higher (you don't burn easily).
- Your doctor has decided phototherapy or oral medications could help, or you've tried them before.
- You are about to start tildrakizumab for the first time through the ILUMYA SUPPORT program, but haven't had your first dose yet.
- You are not taking other oral psoriasis medications (like methotrexate, cyclosporine, or acitretin) and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This trial studies how the immune system responds in adults with moderate-to-severe psoriasis when receiving tildrakizumab. The goal is to better understand treatment effects and immune changes, which may help improve care for people with psoriasis.
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
This trial tests whether tildrakizumab, a biologic medicine, can help people with psoriasis that affects their genital area. It aims to see if the drug reduces symptoms like redness and scaling in those sensitive regions.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.